New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura

Terry Gernsheimer

TERRY GERNSHEIMER, University of Washington Medical Center, Seattle
An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chronic immune thrombocytopenic purpura or ITP. This was in a placebo controlled phase III trial that randomized patients to receive either the novel agent or a placebo. Sarah Maxwell spoke to study author Terry Gernsheimer from the University of Washington during the American Society of Hematology meeting in Atlanta.